HealthDay News - New procedure has good sensitivity, but high number of false positives leads to low specificity
HealthDay News - Optical coherence tomography (OCT), a new imaging technology that allows noninvasive cross-sectional imaging, has high sensitivity for diagnosing cervical cancer, but low specificity, according to a study published in the March issue of Lasers in Surgery and Medicine.
Julia K.S. Gallwas, MD, of Ludwig Maximilian University Munich in Germany, and colleagues investigated the accuracy and reproducibility of OCT in characterizing and grading cervical intraepithelial neoplasia (CIN). OCT images were taken from suspicious and unsuspicious areas in 120 women undergoing colposcopy for suspected CIN. Each woman also underwent biopsy. The OCT images were evaluated separately by two blinded investigators and then compared with the actual histology based on standard grading: normal, inflammation, CIN1, CIN2, CIN3, squamous carcinoma. Sensitivity and specificity of OCT in detecting CIN, as well as interobserver agreement, were measured.
The researchers found that, depending on the chosen threshold, the sensitivity of OCT compared well with the expert colposcopy results. With the threshold at CIN1, the sensitivity was 98 and 96 percent for both investigators, respectively, and the specificity was 39 and 41 percent, respectively, due to a large number of false positive results. With the threshold at CIN2, sensitivity was 86 and 94 percent and specificity increased to 64 and 60 percent, respectively. Interobserver agreement measures were high.
"OCT is highly sensitive in identifying pre-invasive and invasive cancer of the uterine cervix," the authors write. "At present, OCT is not capable to replace colposcopy but it can be used as an adjunct either to guide biopsies or to define the extent of the lesions."
One of the study authors disclosed a financial relationship with Imalux, which provided equipment for the study.
AbstractFull Text (subscription or payment may be required)
Copyright © 2011 HealthDay. All rights reserved.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.